MX2024008835A - Tratamiento con encefalitis autoinmune con satralizumab. - Google Patents
Tratamiento con encefalitis autoinmune con satralizumab.Info
- Publication number
- MX2024008835A MX2024008835A MX2024008835A MX2024008835A MX2024008835A MX 2024008835 A MX2024008835 A MX 2024008835A MX 2024008835 A MX2024008835 A MX 2024008835A MX 2024008835 A MX2024008835 A MX 2024008835A MX 2024008835 A MX2024008835 A MX 2024008835A
- Authority
- MX
- Mexico
- Prior art keywords
- encephalitis
- treatment
- lgi1
- nmdar
- satralizumab
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263300893P | 2022-01-19 | 2022-01-19 | |
| PCT/JP2023/001270 WO2023140269A1 (en) | 2022-01-19 | 2023-01-18 | Treatment of autoimmune encephalitis with satralizumab |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024008835A true MX2024008835A (es) | 2024-07-25 |
Family
ID=87348849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024008835A MX2024008835A (es) | 2022-01-19 | 2023-01-18 | Tratamiento con encefalitis autoinmune con satralizumab. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250127891A1 (https=) |
| EP (1) | EP4466018A4 (https=) |
| JP (1) | JP2025502891A (https=) |
| KR (1) | KR20240145472A (https=) |
| CN (1) | CN118900699A (https=) |
| AU (1) | AU2023209259A1 (https=) |
| CA (1) | CA3243067A1 (https=) |
| IL (1) | IL314213A (https=) |
| MX (1) | MX2024008835A (https=) |
| TW (1) | TW202337495A (https=) |
| WO (1) | WO2023140269A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2892925T3 (es) | 2006-03-31 | 2022-02-07 | Chugai Pharmaceutical Co Ltd | Métodos para controlar la farmacocinética en sangre de anticuerpos |
| EP3620531A4 (en) | 2017-05-02 | 2021-03-17 | National Center of Neurology and Psychiatry | METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS |
| WO2019151418A1 (ja) | 2018-01-31 | 2019-08-08 | 元一 加藤 | Ｉｌ－６阻害剤を含有する喘息の治療剤 |
| IL287220B2 (en) | 2019-04-17 | 2026-03-01 | Univ Hiroshima | A therapeutic agent for urological cancer characterized by administering an IL-6 inhibitor in combination with a CCR2 inhibitor |
| AU2021278562A1 (en) | 2020-05-29 | 2022-12-01 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing formulation |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2206775B1 (en) | 2007-09-26 | 2016-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-il-6 receptor antibody |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| US20120039840A1 (en) | 2008-12-02 | 2012-02-16 | Hunter Christopher A | Use of IL-27-P28 to antagonize IL-6 mediated signaling |
| JP6130983B2 (ja) | 2015-02-27 | 2017-05-17 | 中外製薬株式会社 | Ｉｌ−６関連疾患治療用組成物 |
| JPWO2020202839A1 (https=) * | 2019-03-29 | 2020-10-08 |
-
2023
- 2023-01-18 CN CN202380028068.8A patent/CN118900699A/zh active Pending
- 2023-01-18 KR KR1020247027265A patent/KR20240145472A/ko active Pending
- 2023-01-18 AU AU2023209259A patent/AU2023209259A1/en active Pending
- 2023-01-18 CA CA3243067A patent/CA3243067A1/en active Pending
- 2023-01-18 TW TW112102365A patent/TW202337495A/zh unknown
- 2023-01-18 JP JP2024543040A patent/JP2025502891A/ja active Pending
- 2023-01-18 WO PCT/JP2023/001270 patent/WO2023140269A1/en not_active Ceased
- 2023-01-18 EP EP23743263.8A patent/EP4466018A4/en active Pending
- 2023-01-18 MX MX2024008835A patent/MX2024008835A/es unknown
- 2023-01-18 IL IL314213A patent/IL314213A/en unknown
- 2023-01-18 US US18/729,273 patent/US20250127891A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202337495A (zh) | 2023-10-01 |
| EP4466018A4 (en) | 2026-03-25 |
| CA3243067A1 (en) | 2023-07-27 |
| CN118900699A (zh) | 2024-11-05 |
| IL314213A (en) | 2024-09-01 |
| AU2023209259A1 (en) | 2024-07-18 |
| JP2025502891A (ja) | 2025-01-28 |
| WO2023140269A1 (en) | 2023-07-27 |
| EP4466018A1 (en) | 2024-11-27 |
| US20250127891A1 (en) | 2025-04-24 |
| KR20240145472A (ko) | 2024-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024008835A (es) | Tratamiento con encefalitis autoinmune con satralizumab. | |
| PH12020552018A1 (en) | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies | |
| Fukumoto et al. | HDAC6 inhibition synergizes with anti-PD-L1 therapy in ARID1A-inactivated ovarian cancer | |
| MX2020012905A (es) | Proteínas de unión multiespecíficas y mejoras con estas. | |
| CR20230581A (es) | Anticuerpos anti-CCR8 y usos de los mismos | |
| WO2020014460A8 (en) | HIGH-AFFINITY, ISOFORM-SELECTIVE TGFβ1 INHIBITORS AND USE THEREOF | |
| WO2018151836A8 (en) | Combination therapies for treatment of bcma-related cancers and autoimmune disorders | |
| ZA202005189B (en) | Anti-ngf antibodies and methods thereof | |
| PH12023551241A1 (en) | Fcrn antibodies and methods of use thereof | |
| MX2021002190A (es) | Estrategia de dosificacion que mitiga el sindrome de liberacion de citoquinas para los anticuerpos biespecificos cd3/cd20. | |
| PH12021500031A1 (en) | Anti-il2 receptor gamma antigen-binding proteins | |
| MX2023006482A (es) | Anticuerpos biespecificos especificos para un receptor de tnf coestimulador. | |
| MX2023007945A (es) | Metodos para tratar la alergia al cacahuate y mejorar la inmunoterapia especifica de alergeno del cacahuate mediante la administracion de un antagonista de il-4r. | |
| AU2015287227A8 (en) | Immune-stimulating monoclonal antibodies against human interleukin-2 | |
| WO2023109976A3 (zh) | Ox40抗体及其医药用途 | |
| MX2021014439A (es) | Metodos y aparatos para microorganoesferas derivadas de pacientes. | |
| WO2021119370A8 (en) | Cluster gun system | |
| SG10201810608VA (en) | Methods and systems for a combined transaction by an assignee on behalf of one or more users | |
| MX2024006393A (es) | Tratamiento de enfermedad desmielinante del sistema nervioso central (snc) con satralizumab. | |
| CR20220660A (es) | Métodos para tratar o prevenir infecciones por sars-cov2 y covid-19 con anticuerpos de glicoproteína espícular anti-sars-cov-2 | |
| WO2021207433A3 (en) | Epitopes of sars-cov-2 neutralizing antibodies | |
| MX2021013427A (es) | Metodos para tratar o prevenir el asma mediante la administracion un antagonista de il-33. | |
| EP4530296A3 (en) | Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies | |
| MX2022001604A (es) | Anticuerpos anti bdca-2. | |
| ZA202107426B (en) | Bispecific antibodies |